Philippe Quétin

Dr. Philippe Quétin


Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
MMMatthieu Martin
Matthieu Martin
BSBruno Sciolla
Bruno Sciolla
MSMichaël Sdika
Michaël Sdika
PQPhilippe Quétin
Philippe Quétin
PDPhilippe Delachartre
Philippe Delachartre

1 January 1994 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
MGMichèle Gouault-Heilmann
Michèle Gouault-Heilmann
PQPhilippe Quétin
Philippe Quétin
MDMarie Dreyfus
Marie Dreyfus
SGSophie Gandrille
Sophie Gandrille
JEJoseph Emmerich
Joseph Emmerich
MGMichel Guesnu
Michel Guesnu

1 March 2024 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
PQPhilippe Quétin
Philippe Quétin
NLNicolas Leboucq
Nicolas Leboucq
CBCharlotte Boyer
Charlotte Boyer
FCFrançoise Crozier
Françoise Crozier
PDPhilippe Delachartre
Philippe Delachartre
OCOlivier Claris
Olivier Claris

26 April 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
LFLaurence FAYOL
Laurence FAYOL
JYJilnar Yaacoub
Jilnar Yaacoub
MBMarine Baillat
Marine Baillat
CRClotilde Des Robert
Clotilde Des Robert
VPVanessa Pauly
Vanessa Pauly
FBFarid Boubred
Farid Boubred
In preterm infants, early nutrient intake during the first week of life often depends on parenteral nutrition. This study aimed to evaluate the influence of standardized parenteral nutrition using three-in-one double-chamber solutions (3-in-1 STD-PN) on early neonatal growth in a cohort of moderately preterm (MP) infants. This population-based, observational cohort study included preterm infants admitted to neonatal centers in the southeast regional perinatal network in France. During the study period, 315 MP infants with gestational ages between 320/7 and 346/7 weeks who required parenteral nutrition from birth until day-of-life 3 (DoL3) were included; 178 received 3-in-1 STD-PN solution (56.5%). Multivariate regression was used to assess the factors associated with the relative body-weight difference between days 1 and 7 (RBWD DoL1-7). Infants receiving 3-in-1 STD-PN lost 36% less body weight during the first week of life, with median RBWD DoL1-7 of −2.5% vs. −3.9% in infants receiving other PN solutions (p < 0.05). They also received higher parenteral energy and protein intakes during the overall first week, with 85% (p < 0.0001) and 27% (p < 0.0001) more energy and protein on DoL 3. After adjusting for confounding factors, RBWD DoL1-7 was significantly lower in the 3-in-1 STD-NP group than in their counterparts, with beta (standard deviation) = 2.08 (0.91), p = 0.02. The use of 3-in-1 STD-PN provided better energy and protein intake and limited early weight loss in MP infants.